{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:37:37Z","timestamp":1785285457585,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s12325-015-0207-3","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T01:28:48Z","timestamp":1431394128000},"page":"429-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study"],"prefix":"10.1007","volume":"32","author":[{"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Weiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"issue":"1","key":"207_CR1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/11587620-000000000-00000","volume":"71","author":"KR Connolly","year":"2011","unstructured":"Connolly KR, Thase ME. If at first you don\u2019t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43\u201364.","journal-title":"Drugs."},{"issue":"2","key":"207_CR2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/15622970801981606","volume":"9","author":"HJ Moller","year":"2008","unstructured":"Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry. 2008;9(2):102\u201314.","journal-title":"World J Biol Psychiatry."},{"issue":"5","key":"207_CR3","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.4088\/JCP.8133tx4c","volume":"72","author":"ME Thase","year":"2011","unstructured":"Thase ME. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. J Clin Psychiatry. 2011;72(5):e18.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"207_CR4","first-page":"57","volume":"42","author":"R Fleurence","year":"2009","unstructured":"Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57\u201390.","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl 1","key":"207_CR5","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1007\/s40263-012-0031-0","volume":"27","author":"AA Patkar","year":"2013","unstructured":"Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(Suppl 1):S29\u201337.","journal-title":"CNS Drugs."},{"issue":"5","key":"207_CR6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1345\/aph.1Q326","volume":"46","author":"C Taneja","year":"2012","unstructured":"Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann Pharmacother. 2012;46(5):642\u20139.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"207_CR7","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/14656566.2012.656590","volume":"13","author":"DS Cha","year":"2012","unstructured":"Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13(11):1587\u201398.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"207_CR8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/phar.1204","volume":"33","author":"BM Wright","year":"2013","unstructured":"Wright BM, Eiland EH III, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy. 2013;33(3):344\u201359.","journal-title":"Pharmacotherapy."},{"issue":"2","key":"207_CR9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0269881113507640","volume":"28","author":"P Turner","year":"2014","unstructured":"Turner P, Kantaria R, Young AH. A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J Psychopharmacol. 2014;28(2):85\u201398.","journal-title":"J Psychopharmacol."},{"issue":"8","key":"207_CR10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1176\/appi.ps.201300288","volume":"65","author":"KR Gersing","year":"2014","unstructured":"Gersing KR, Sheehan JJ, Burchett B, et al. Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set. Psychiatr Serv. 2014;65(8):1062\u20135.","journal-title":"Psychiatr Serv"},{"key":"207_CR11","doi-asserted-by":"crossref","unstructured":"Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71 Suppl E1:e08.","DOI":"10.4088\/JCP.9058se1c.08gry"},{"issue":"2","key":"207_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/070674370204700202","volume":"47","author":"SN Ghaemi","year":"2002","unstructured":"Ghaemi SN, Ko JY, Goodwin FK. \u201cCade\u2019s disease\u201d and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry. 2002;47(2):125\u201334.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"207_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0010-440X(00)90140-8","volume":"41","author":"M Fava","year":"2000","unstructured":"Fava M, Rankin MA, Wright EC, et al. Anxiety disorders in major depression. Compr Psychiatry. 2000;41(2):97\u2013102.","journal-title":"Compr Psychiatry"},{"issue":"8","key":"207_CR14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.157.8.1337","volume":"157","author":"M Zimmerman","year":"2000","unstructured":"Zimmerman M, McDermut W, Mattia JI. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry. 2000;157(8):1337\u201340.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"207_CR15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0447.2009.01512.x","volume":"122","author":"MM Fichter","year":"2010","unstructured":"Fichter MM, Quadflieg N, Fischer UC, Kohlboeck G. Twenty-five-year course and outcome in anxiety and depression in the Upper Bavarian Longitudinal Community Study. Acta Psychiatr Scand. 2010;122(1):75\u201385.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"207_CR16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-0447.2011.01677.x","volume":"123","author":"D Rhebergen","year":"2011","unstructured":"Rhebergen D, Batelaan NM, de Graaf R, et al. The 7-year course of depression and anxiety in the general population. Acta Psychiatr Scand. 2011;123(4):297\u2013306.","journal-title":"Acta Psychiatr Scand."},{"issue":"6","key":"207_CR17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4088\/JCP.13m08961","volume":"75","author":"M Zimmerman","year":"2014","unstructured":"Zimmerman M, Chelminski I, Young D, Dalrymple K, Walsh E, Rosenstein L. A clinically useful self-report measure of the DSM-5 anxious distress specifier for major depressive disorder. J Clin Psychiatry. 2014;75(6):601\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"207_CR18","doi-asserted-by":"crossref","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","volume":"10","author":"GI Spielmans","year":"2013","unstructured":"Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3):e1001403.","journal-title":"PLoS Med."},{"issue":"7","key":"207_CR19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.pnpbp.2010.03.023","volume":"34","author":"CU Pae","year":"2010","unstructured":"Pae CU, Sohi MS, Seo HJ, et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1165\u201373.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"207_CR20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11538980-000000000-00000","volume":"25","author":"CU Pae","year":"2011","unstructured":"Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2):109\u201327.","journal-title":"CNS Drugs."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0207-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T19:52:52Z","timestamp":1566676372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0207-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["207"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0207-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}